Entero Healthcare Solutions Ltd. - Asset Resilience Ratio

Latest as of March 2026: 3.61%

Entero Healthcare Solutions Ltd. (ENTERO) has an Asset Resilience Ratio of 3.61% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

Rs1.30 Billion
≈ $14.05 Million USD Cash + Short-term Investments

Total Assets

Rs36.00 Billion
≈ $389.35 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2019–2025)

This chart shows how Entero Healthcare Solutions Ltd.'s Asset Resilience Ratio has changed over time. See Entero Healthcare Solutions Ltd. financial flexibility index to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Entero Healthcare Solutions Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market value of Entero Healthcare Solutions Ltd..

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Rs0.00 0%
Short-term Investments Rs1.30 Billion 3.61%
Total Liquid Assets Rs1.30 Billion 3.61%

Asset Resilience Insights

  • Limited Liquidity: Entero Healthcare Solutions Ltd. maintains only 3.61% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Entero Healthcare Solutions Ltd. Industry Peers by Asset Resilience Ratio

Compare Entero Healthcare Solutions Ltd.'s asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Cardinal Health Inc
NYSE:CAH
Medical Distribution 4.78%
Qingdao Baheal Medical INC.
SHE:301015
Medical Distribution 4.28%
China National Accord Medicines Corp Ltd
SHE:200028
Medical Distribution -1.21%
Millennium Pharmacon International
JK:SDPC
Medical Distribution -0.72%
COSMOS HEALTH NEW DL-01
F:V67A
Medical Distribution 0.07%
Sigma Healthcare Ltd
AU:SIG
Medical Distribution 0.03%
Ebos Group Ltd
AU:EBO
Medical Distribution 0.00%
Mayne Pharma Group Ltd
AU:MYX
Medical Distribution 4.00%

Annual Asset Resilience Ratio for Entero Healthcare Solutions Ltd. (2019–2025)

The table below shows the annual Asset Resilience Ratio data for Entero Healthcare Solutions Ltd..

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-09-30 3.61% Rs1.30 Billion
≈ $14.05 Million
Rs36.00 Billion
≈ $389.35 Million
+1.48pp
2024-09-30 2.13% Rs575.55 Million
≈ $6.22 Million
Rs27.03 Billion
≈ $292.27 Million
-29.54pp
2023-09-30 31.67% Rs7.43 Billion
≈ $80.32 Million
Rs23.45 Billion
≈ $253.60 Million
+25.87pp
2022-09-30 5.80% Rs814.82 Million
≈ $8.81 Million
Rs14.04 Billion
≈ $151.85 Million
+0.57pp
2021-09-30 5.23% Rs588.90 Million
≈ $6.37 Million
Rs11.26 Billion
≈ $121.77 Million
-0.83pp
2020-09-30 6.06% Rs505.10 Million
≈ $5.46 Million
Rs8.34 Billion
≈ $90.17 Million
+2.37pp
2019-09-30 3.69% Rs276.62 Million
≈ $2.99 Million
Rs7.49 Billion
≈ $81.03 Million
--
pp = percentage points

About Entero Healthcare Solutions Ltd.

NSE:ENTERO India Medical Distribution
Market Cap
$585.06 Million
Rs54.10 Billion INR
Market Cap Rank
#11174 Global
#565 in India
Share Price
Rs1243.00
Change (1 day)
+1.70%
52-Week Range
Rs949.20 - Rs1354.40
All Time High
Rs1549.55
About

Entero Healthcare Solutions Limited engages in the distribution and marketing of pharmaceutical, surgical products and other allied services in India. The company involved in the distribution of generic formulations, active pharmaceutical ingredients, surgical consumables, rehabilitation products and devices, over the counter medical products, nutraceuticals, biosimilars, and biologics. It also p… Read more